Tumor necrosis factor (TNF) and Fas ligand (FasL) have been implicated in the pathogenesis of graftversus-host disease (GVHD), which is a major complication after allogeneic bone marrow transplantation. We have examined the ameliorating effect of a metalloproteinase inhibitor (KB-R7785) that inhibits TNF-␣ and FasL release in a murine acute GVHD model after bone marrow transplantation. Administration of KB-R7785 to irradiated (BALB/c ؋ C57BL/6) F1 mice that received C57BL/6 bone marrow cells and spleen cells reduced the mortality and weight loss in association with minimal signs of GVHD pathology in the liver, intestine, and hematopoietic tissues. The KB-R7785 treatment did not affect hematopoietic reconstitution by donor cells. Therefore, KB-R7785 could be a potent therapeutic agent for GVHD after bone marrow transplantation.
It is well known that the tumor necrosis factor (TNF)-␣ is an important cytokine in GVHD, and also in venoocclusive disease (VOD) after human BMT. 4 It has been shown that serum levels of TNF-␣ are increased in patients undergoing GVHD after allogeneic BMT and that administration of anti-TNF-␣ antibody markedly reduced the weight loss and mortality in a mouse model of GVHD. 5 A clinical phase I-II study, using an anti-TNF-␣ monoclonal antibody (mAb) during pretransplant conditioning as an additive prophylaxis of acute GVHD after BMT, resulted in some beneficial effects. 6 Recently, the ligand for Fas (FasL) has also been implicated in the pathogenesis of GVHD. Fas (APO-1, CD95) is a member of the TNF receptor family and transmits an apoptotic cell death signal upon ligation by FasL. 7 Fas is expressed in various tissues, including the skin, liver and intestine which are target tissues of GVHD. 8 A critical involvement of FasL in the development of hepatic and cutaneous GVHD pathology has been demonstrated in a murine model of acute GVHD. 9 A partial contribution of FasL to mortality was also noted in a different murine model of acute GVHD. 10 We also recently demonstrated different contributions of TNF-␣ and FasL to GVHD pathologies and a complete protection from mortality by neutralization of both TNF-␣ and FasL. 11 TNF-␣ and FasL are type II integral membrane proteins belonging to the TNF family and are predominantly expressed on activated macrophages and activated T cells, respectively. 12 It is known that TNF-␣ is efficiently shed from the macrophage surface as a soluble cytokine. Several recent studies have shown that some metalloproteinases mediate the processing of TNF-␣ which can be inhibited by hydroxamic acid-based metalloproteinase inhibitors. [13] [14] [15] [16] [17] We previously found that FasL is also efficiently released from the activated T cell surface and that some metalloproteinase inhibitors could inhibit shedding. 18 Moreover, we recently demonstrated a potent ameliorating effect of a metalloproteinase inhibitor (KB-R7785), which inhibits the release of both TNF-␣ and FasL, in a lethal acute GVHD model where parental C57BL/6 splenocytes were injected into unirradiated (BALB/c ϫ C57BL/6)F1 mice. 19 However, the beneficial effects of such a metalloproteinase inhibitor remain to be determined in a BMT model of acute GVHD which is more relevant to clinical situations. In this context, we examined the therapeutic effect of KB-R7785 in a murine acute GVHD model. ) mice were purchased from SLC (Shizuoka, Japan) and maintained in our animal facilities. Prevention of lethal acute GVHD by KB-R7785. Acute GVHD was induced in irradiated CBF1 mice by i.v. injection of 1 ϫ 10 7 bone marrow cells and 5 ϫ 10 7 spleen cells from B6 mice on day 0. Ten mice in each group were given s.c. 2 mg KB-R7785 in 0.5% CMC (ț) or 0.5% CMC (᭺) every day from day 0 to day 40. As a control, irradiated CBF1 mice were injected with 1 ϫ 10 7 bone marrow cells and 5 ϫ 10 7 spleen cells from CBF1 mice (). Survival (a) was monitored every day until day 35. Body weight (b) was measured at the indicated days and is shown as mean Ϯ s.d. of 3-10 mice. In (b), body weight of age-matched normal CBF1 (᭛) is also plotted.
Materials and methods

Mice
Reagents
The hydroxamic acid-based metalloproteinase inhibitor KB-R7785, [4- (N-hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-l-phenylglycine-N-methylamide, was synthesized by Kanebo Ltd (Osaka, Japan). 20 For in vivo administration, KB-R7785 was suspended in 0.5% carboxymethyl cellulose (CMC) at 10 mg/ml.
Induction of acute GVHD
GVHD was induced in lethally irradiated (8 Gy) CBF1 mice (10 mice in each group) by i.v. injections of 1 ϫ 10 7 bone marrow cells and 5 ϫ 10 7 spleen cells from B6 mice on day 0. Some mice were given 2 mg of KB-R7785 in 200 l of 0.5% CMC or 200 l of 0.5% CMC alone s.c. every day from day 0 to day 40. As a control, irradiated CBF1 mice were injected with 1 ϫ 10 7 bone marrow cells and 5 ϫ 10 7 spleen cells from CBF1 mice. Survival was monitored until day 40. Body weight of the survivors was measured weekly. Sera were obtained weekly and analyzed by TNF-␣ ELISA. On day 28, three mice in each group were sacrificed and their livers, intestines, and spleens were subjected to histopathological examination.
Histopathology
Tissues were fixed in 10% buffered formalin and paraffin embedded. Sections were stained with hematoxylin and eosin and examined microscopically.
Flow cytometric analysis
Splenocytes were prepared from normal CBF1, GVHD, or KB-R7785-treated mice on day 28 ϩ T, and B220 ϩ B cells of recipient or donor origin were calculated from the total numbers of splenocytes recovered and the percentages of each subpopulation.
Hematological analysis
Peripheral blood was obtained from the retro-orbital sinus. White blood cells, hematocrit and platelets were counted on a Sysmex E-4000 counter (TOA Medical Electronics, Kobe, Japan). Neutrophils were counted after WrightGiemsa staining. Histopathological examination. Induction of acute GVHD and administration of KB-R7785 were performed as described in Figure 1 . On day 28, three mice in each group were sacrificed. Paraffin sections of the liver, intestine and spleen were stained by hematoxylin and eosin. Sections from age-matched normal CBF1 are also represented as a control. Original magnification, ϫ100.
TNF-␣ ELISA
Serum TNF-␣ levels were measured by using an ELISA system according to the instructions of the supplier (Amersham International, Buckinghamshire, UK).
Statistical analysis
Significant differences were determined by Mann-Whitney U test for the survival rate and by the Student's t-test for cell numbers. P values less than 0.05 were considered statistically significant.
Results
Effect of KB-R7785 on GVHD-induced mortality and weight loss
An acute type of GVHD was induced by i.v. injection of B6 bone marrow cells and splenocytes into lethally irradiated CBF1 mice. These mice were given 2 mg KB-R7785 in 0.5% CMC or 0.5% CMC vehicle alone daily from day 0 to day 40. For comparison, another group of mice were reconsituted by i.v. injection of CBF1 bone marrow cells and splenocytes into CBF1 mice. As shown in Figure 1a , all the 0.5% CMC-treated control mice undergoing GVHD died within 35 days. In these mice, clinical symptoms of acute GVHD, such as hair ruffling, reduced mobility, and weight loss (Figure 1b ) became apparent in 2 weeks. However, skin lesions such as alopecia and desquamating rash did not become apparent in this model. The administration of KB-R7785 markedly reduced the mortality and eight of 10 mice survived for 40 days ( Figure  1a ). The weight loss was not significantly ameliorated during the first 3 weeks, but the body weight of survivors was improved thereafter and recovered to the F1→F1 BMT control levels until day 40 (Figure 1b) . No apparent clinical symptoms of acute GVHD were observed in these mice.
An elevated serum level of TNF-␣ (128.9 Ϯ 91.6 pg/ml) was observed in the CMC-treated GVHD mice on day 7. In contrast, serum TNF-␣ was not detectable (Ͻ50 pg/ml) in the KB-R7785-treated mice.
Effect of KB-R7785 on GVHD-associated histopathologies
The development of skin lesions was not apparent in the present model of GVHD as also estimated by histological examination (not shown).
In the liver from the control mice undergoing GVHD, a massive infiltration of mononuclear cells and fibrosis was generally observed in the parenchyma (Figure 2a ). In contrast, such inflammatory changes were limited to foci at the periportal areas in the liver from the KB-R7785-treated mice (Figure 2b) .
The gut from the control mice undergoing GVHD exhib- ited dilatation, flattening of the villi, and elevation of the crypts, which are characteristics of intestinal GVHD (Figure 2d ). All these lesions were virtually absent in the KB-R7785-treated mice (Figure 2e ). The spleen from the control GVHD mice showed a marked lymphoid atrophy and structural disorganization (Figure 2g ). In contrast, such changes were minimal in the KB-R7785-treated mice (Figure 2h) .
Effect of KB-R7785 on GVHD-associated lymphoid hypoplasia
As shown in Figure 3 ϩ T, CD8 ϩ T and B220 ϩ B cells were substantially decreased as compared to normal CBF1 and the F1→F1 control mice (Table 1 ). In contrast, no significant decrease of T and B cells was observed in the KB-R7785-treated mice as compared to the F1→F1 control mice.
Effect of KB-R7785 on hematopoietic reconstitution after BMT
We also examined whether the administration of KB-R7785 had any adverse effects on hematopoietic reconstitution after BMT. As shown in Figure 4a , the recovery of blood platelets, hematocrit, and neutrophils on day 28 was almost comparable between the KB-R7785-treated and untreated F1→F1 BMT mice. Similarly, no significant difference in the recovery of blood platelets, hematocrit, and neutrophils on day 28 was obserbed between the KB-R7785-treated B6→F1 BMT mice and the F1→F1 BMT mice (Figure 4b ).
Discussion
Recent studies have implicated TNF-␣ and FasL in the pathogenesis of GVHD. [4] [5] [6] 9, 10 Recently we have demonstrated differential contributions of TNF-␣ and FasL to GVHD pathologies by administering neutralizing anti-TNF-␣ and/or anti-FasL mAb into a parent (B6) to F1 (CBF1) spleen cell transfer model of lethal acute GVHD.
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Hepatic lesions were improved by anti-FasL, but not by anti-TNF-␣, mAb. Conversely, intestinal lesions were improved by anti-TNF-␣, but not by anti-FasL, mAb. Cutaneous and splenic lesions were improved by either mAb. Consequently, while the treatment with either antiFasL or anti-TNF-␣ mAb alone significantly delayed the mortality and improved the body weight, complete protection was achieved by the administration of both mAbs. We have also demonstrated similarly complete protection by the administration of a metalloproteinase inhibitor (KB- 7 bone marrow cells and 5 ϫ 10 7 spleen cells from B6 mice on day 0. Ten mice in each group were given s.c. 2 mg KB-R7785 in 0.5% CMC (b) or 0.5% CMC (᭺) every day from day 0 to day 40. As a control, irradiated CBF1 mice were injected with 1 ϫ 10 7 bone marrow cells and 5 ϫ 10 7 spleen cells from CBF1 mice (). All these mice were bred on the indicated days and blood neutrophils, platelets, and hematocrit were measured. Data are shown as mean Ϯ s.d. of 3-10 mice.
Table 1
Effect of KB-R7785 on GVHD-associated lymphoid hypoplasia Cell numbers of B220 ϩ B, CD4 ϩ T and CD8 ϩ T cells in splenocytes from normal CBF1, F1→F1 BMT, B6→F1 BMT, B6→F1 BMT ϩ KB-R7785-treated mice on day 28 were calculated from the total numbers of splenocytes and the percentages of each subpopulation determined by two-color flow cytometric analysis represented in Figure 3 . Data are shown as the mean Ϯ s.d. of three to five mice. *P Ͻ 0.05 compared to the F1→F1 group. R7785), which inhibits the shedding of both TNF-␣ and FasL, into the same B6→CBF1 spleen cell transfer model. 19 The present study was performed to explore the ameliorating effect of KB-R7785 in a BMT model of acute GVHD, which is more relevant to clinical situations. In addition, a potential adverse effect of KB-R7785 on hematopoietic reconstitution after BMT was another subject of this study.
As was the case in the spleen cell transfer model, 19 the administration of KB-R7785 almost completely abolished mortality ( Figure 1a ) and improved the GVHD-associated pathologies in the liver, intestine and spleen (Figure 2 ) in the present BMT model. A subtle difference was observed in the improvement of weight loss. In the former case of spleen cell transfer model, no significant weight loss was observed as compared to the age-matched normal mice during the KB-R7785 treatment. 19 In contrast, in the present BMT model, weight loss was not significantly ameliorated during the first 3 weeks but then gradually improved to the F1→F1 BMT control levels by day 40 (Figure 1b ). This apparent difference seems to result from the total body irradiation (TBI) of the recipients, which was performed in the present BMT model but not in the former spleen cell transfer model. It has been shown that TBI by itself induced gastrointestinal damage and release of inflammatory cytokines such as TNF-␣ and IL-1␤, and thus exacerbates acute GVHD. 21 Therefore, the weight loss during the first 3 weeks after BMT may be mediated by gastrointestinal damage by irradiation, where the secretion of TNF-␣ or FasL plays a minor role.
As observed in the spleen cell transfer model, 19 the KB-R7785 treatment prevented splenic atrophy ( Figure 2 ) and both T and B lymphoid hypoplasia (Table 1) in the present BMT model. In our previous study where B6 spleen cells were infused into unirradiated CBF1 recipients, KB-R7785 treatment preserved both host and donor lymphocytes, resulting in a stable chimeric state. 19 In the present BMT model, where CBF1 recipients were lethally irradiated before the infusion of B6 bone marrow cells and spleen cells, splenic lymphocytes were completely replaced by donor-derived lymphocytes on day 28 after BMT ( Figure  3 ). The numbers of B cells, CD4
ϩ T cells and CD8 ϩ T cells in the KB-R7785-treated B6→F1 BMT mice were almost comparable to those in the F1→F1 BMT mice (Table 1) . This preservation of donor lymphocytes may result from inhibition of activation-induced apoptosis, in which both FasL and TNF-␣ play critical roles. 9, 10 It remains to be determined whether tolerance to the host alloantigen has been established in the donor lymphocytes. Alternatively, the efficient reconstitution by donor lymphocytes may result from inhibition of suppressive effects of TNF-␣ and FasL on hematopoiesis (Refs 19, 22-24, and our unpublished data).
The hydroxamic acid-based metalloproteinase inhibitor, KB-R7785, was originally developed against matrix metalloproteinases (MMP) including collagenases, stromelysins and gelatinases, which are directly involved in tissue degeneration and tissue infiltration by inflammatory cells. A major role for MMP in T cell-mediated gut injury has been suggested recently. 25 Therefore, the blockade of these processes in GVHD-associated inflammation may also contribute to the beneficial effect of KB-R7785. On the other hand, such MMP inhibitors may also affect hematopoietic reconstitution after BMT by modulating the migration of hematopoietic progenitors and their interaction with stroma. We addressed this possibility by giving KB-R7785 to the F1→F1 BMT mice but found no adverse effect on the recovery of blood platelets, hematocrit, and neutrophils (Figure 4a ). This was also true for the KB-R7785-treated B6→F1 BMT mice as compared to the F1→F1 BMT mice (Figure 4b ). These results indicate that the KB-R7785 treatment does not have an adverse effect on hematopoietic reconstitution by donor cells after BMT.
In conclusion, this study has shown a potent ameliorating effect of KB-R7785 in an acute GVHD model after BMT without an adverse effect on hematopoietic reconstitution. The hydroxamic acid-based MMP inhibitor similar to KB-R7785 (Marimastat) has already been subjected to phase I/II studies for the treatment of pancreatic, prostatic, and ovarian cancers with no serious adverse effect and minimal toxicity. [26] [27] [28] Therefore, the MMP inhibitors are expected to be immediately applicable for the clinical treatment of acute GVHD patients after BMT.
